Healthcare
Quantum BioPharma Ltd.(QNTM)
Live Price
Offline$3.83
-4.25% today
1Y Change
-83.36%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- $20.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +35.1%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Quantum BioPharma Ltd. (QNTM) is a Healthcare stock with a market cap of $20.00M and listed on NASDAQ. The stock last traded around $3.83 and down 83.4% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +35.1%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +35.1%, free cash flow -21.9% with operating margin 0.0% and ROIC -220.0%. Stock Foundry combines QNTM price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 8, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +35.1%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +8.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 8, 2026 | โ | +3.7% | +39.5% | -17.0% |
2026 Mar 26, 2026 | +30.5% | +24.5% | +3.9% | -5.7% |
2025 Nov 7, 2025 | -525.0% | -5.8% | -17.4% | +13.7% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
QNTM
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
QNTM Max Drawdown
-92.81%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for QNTM and SPY.
Company Overview
Quantum BioPharma Ltd.
NASDAQ Global Market
Quantum BioPharma Ltd., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. The company was formerly known as FSD Pharma Inc. and changed its name to Quantum BioPharma Ltd., in August 2024. Quantum BioPharma Ltd., is headquartered in Toronto, Canada.
- Leadership
- Zeeshan Saeed
- IPO Date
- Jun 8, 2018
- Employees
- 17
- Street Address
- 55 University Ave.
- Mailing
- Toronto, ON, M5J 2H7
- Region
- Toronto, ON, CA
- Reporting Currency
- USD
- Investor Line
- +1 416 854 8884
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- 3.1
Growth
- Revenue
- 0.0%
- EPS
- +35.1%
- Free Cash Flow
- -21.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -418.5%
- ROIC
- -220.0%
Balance Sheet
- Debt/Equity
- 0.27
- Current Ratio
- 1.07
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.